SCHEMBL5294292

SCHEMBL5294292

CCOC(=O)Cc1cc(C)nn1-c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.53
STAT1 P42224 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
ALDH1A1 P00352 4/20 0.49
KDM4E B2RXH2 2/20 0.49
HSD17B10 Q99714 2/20 0.49
TSHR P16473 1/20 0.49
PDE4D Q08499 1/20 0.49
NTRK1 P04629 1/20 0.49
KMT2A Q03164 2/20 0.48
L3MBTL1 Q9Y468 4/20 0.48
MAPT P10636 2/20 0.47
HPGD P15428 2/20 0.47
KLK6 Q92876 1/20 0.46
GAA P10253 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
ATM Q13315 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5294281 0.85 HTT (0.52) LMNASMN1; SMN2ALDH1A1KDM4EHSD17B10
SCHEMBL5806384 0.84 NTRK1 (0.55) LMNASTAT1SMN1; SMN2ALDH1A1TSHR
SCHEMBL14722368 0.80 ALDH1A1 (0.48) LMNASTAT1SMN1; SMN2ALDH1A1TSHR
SCHEMBL17453326 0.79 SMN1; SMN2 (0.47) LMNASTAT1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL6422295 0.77 KMT2A (0.65) LMNASTAT1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL2612161 0.77 MAPK1 (0.58) LMNASTAT1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL16050054 0.77 MAPK1 (0.61) LMNASMN1; SMN2ALDH1A1KDM4EHSD17B10
SCHEMBL2824324 0.76 KDM4E (0.48) LMNASMN1; SMN2ALDH1A1KDM4EHSD17B10
SCHEMBL5111929 0.76 KMT2A (0.54) LMNAALDH1A1KDM4EHSD17B10TSHR
SCHEMBL2355067 0.76 MAPK1 (0.56) SMN1; SMN2ALDH1A1KDM4EHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO disclosed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 LMNA 3704/4885STAT1 4289/4885SMN1; SMN2 3894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.